These new NIH-Start-up Licenses minimize the barriers to entry faced by start-up companies under exclusive licenses and provide a structure that encourages and supports the commercial development of early stage NIH and FDA technologies.
Via NIH TechTransfer Office:
The National Institutes of Health (NIH) through the Office of Technology Transfer has developed a new short-term exclusive Start-Up Evaluation License Agreement (Start-up EELA) and a Start-up Exclusive Commercial License Agreement (Start-up ECLA) to facilitate licensing of intramural NIH and Food and Drug Administrative (FDA) inventions to start-up companies.
These new NIH Start-up Licenses are offered to assist start-up companies less than 5 years old, less than $5M in capital raised, and with fewer than 50 employees to obtain an exclusive license from the NIH for early stage biomedical inventions. These Start-Up Licenses will be offered to companies developing drugs, vaccines or therapeutics from NIH or FDA patented or patent pending technologies.
The start-up company must license at least one US patent and commit to developing a product or service for the US market. They may also include in the license related NIH/FDA patents filed in other countries if they commit to bringing products to markets in those countries as well.
The program will be offered during FY2012 – October 1, 2011 through September 30, 2012 – after which time, it will be evaluated for its success and possible extension. Companies can identify technologies of interest by searching Licensing Opportunities and follow through with the listed contact.
For general questions about this program, please contact Richard Rodriguez, Director, Division of Technology Development and Transfer, OTT at firstname.lastname@example.org.
READ FULL ANNOUNCEMENT [web]